Could combination treatment with SGLT2i & endothelin receptor antagonists further reduce risk of kidney failure in people with chronic kidney disease?
Design and rationale of the phase 2B ZENITH-CKD trial
1
22
67
Replies
@brendonneuen
@ChristosArgyrop
@NDTsocial
Are the renoprotective properties of SGTL2i’s potentially associated with their benefits in heart failure? (iirc it was a reduction in all-cause mortality?)
0
0
0